Biohaven acquires exclusive global rights to develop and commercialize first-in-class transient receptor potential melastatin-3 (TRPM3) channel antagonists
The lead candidate, BHV-2100, is planned to enter clinical development in the first half of 2023 for the treatment of neuropathic pain
https://finance.yahoo.com/news/biohaven-enters-exclusive-license-research-050100767.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.